Cargando…

The association of urinary epidermal growth factors with ADPKD disease severity and progression

BACKGROUND: The epidermal growth factor receptor (EGFR) pathway is involved in kidney tissue repair and growth. Preclinical interventional data and scarce human data have suggested a role for this pathway in the pathophysiology of autosomal dominant polycystic kidney disease (ADPKD), while other dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harskamp, Laura R, Perez-Gomez, Maria Vanessa, Heida, Judith E, Engels, Gerwin E, van Goor, Harry, van den Heuvel, Marius C, Streets, Andrew J, Ong, Albert C M, Ortiz, Alberto, Gansevoort, Ron T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article - Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539218/ https://www.ncbi.nlm.nih.gov/pubmed/36914219 http://dx.doi.org/10.1093/ndt/gfad050

Ejemplares similares

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD
por: Messchendorp, A. Lianne, et al.
Publicado: (2019)

No Change in Nocturia After NOCTURNE
por: Meijer, Esther, et al.
Publicado: (2020)

Acid-Base Homeostasis During Vasopressin V2 Receptor Antagonist Treatment in Autosomal Dominant Polycystic Kidney Disease Patients
por: Heida, Judith E., et al.
Publicado: (2021)

Urinary Biomarkers at Early ADPKD Disease Stage
por: Petzold, Katja, et al.
Publicado: (2015)

Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study
por: Winterbottom, Jean, et al.
Publicado: (2022)

Heterogeneous Cardiovascular Profiles in CKD: ADPKD Versus non-ADPKD
por: Au, Eric H.K., et al.
Publicado: (2022)

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model
por: McEwan, Phil, et al.
Publicado: (2018)

Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment
por: Zittema, Debbie, et al.
Publicado: (2017)

Antenatally Diagnosed ADPKD
por: Aldridge, Melanie, et al.
Publicado: (2018)

Intrafamilial Variability of ADPKD
por: Lanktree, Matthew B., et al.
Publicado: (2019)

Dietary Care for ADPKD Patients: Current Status and Future Directions
por: Carriazo, Sol, et al.
Publicado: (2019)

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression
por: Messchendorp, A. Lianne, et al.
Publicado: (2017)

Renal Volume in ADPKD Patient Evaluation
por: Galliani, M., et al.
Publicado: (2020)

Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients
por: Dekker, Shosha E.I., et al.
Publicado: (2022)

Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD
por: Makabe, Shiho, et al.
Publicado: (2021)

The BC ADPKD Network: A Comprehensive Provincial Approach to Support Specialized and Locally Delivered Multidisciplinary ADPKD Care
por: Bevilacqua, M., et al.
Publicado: (2021)

The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2022)

Simultaneous laparoscopic nephrectomy in ADPKD
por: Baishya, Ramen Kumar, et al.
Publicado: (2010)

Polycystins, ADPKD, and Cardiovascular Disease
por: Kuo, Ivana Y., et al.
Publicado: (2019)

Defining Cardiac Dysfunction in ADPKD
por: Kuo, Ivana Y.
Publicado: (2023)

Cardiovascular Manifestations and Management in ADPKD
por: Sagar, Priyanka S., et al.
Publicado: (2023)

Characteristics of Patients with End-Stage Kidney Disease in ADPKD
por: Shukoor, Shehbaz S., et al.
Publicado: (2020)

Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD
por: Chedid, Maroun, et al.
Publicado: (2022)

OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2023)

The importance of quantifying genetic heterogeneity in ADPKD
por: Chapman, Arlene B.
Publicado: (2014)

Renal Transcatheter Arterial Embolization for ADPKD
por: Oda, Yasuhiro, et al.
Publicado: (2020)

The imaging of total kidney volume in ADPKD
por: Cavoli, Gioacchino Li, et al.
Publicado: (2020)

The Impact of COVID-19 on Patients With ADPKD
por: Kutky, Meherzad, et al.
Publicado: (2021)

Germline Mutations for Kidney Volume in ADPKD
por: Kataoka, Hiroshi, et al.
Publicado: (2021)

Imaging Biomarkers in Young Patients With ADPKD
por: Yang, Xinyi, et al.
Publicado: (2023)

Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants
por: Hallows, Kenneth R., et al.
Publicado: (2022)

Prolonged ex-vivo normothermic kidney perfusion: The impact of perfusate composition
por: Pool, Merel B. F., et al.
Publicado: (2021)

Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
por: Ong, Albert C M, et al.
Publicado: (2022)

Congenital Hepatic Fibrosis as an Early Sign of Presentation of ADPKD
por: Sila, L., et al.
Publicado: (2023)

MR Brain Screening in ADPKD Patients: To Screen or not to Screen?
por: Capelli, I., et al.
Publicado: (2021)

Acute Kidney Injury in ADPKD Patients with Pneumonia
por: Franco Palacios, Carlos, et al.
Publicado: (2011)

ADPKD: Prototype of Cardiorenal Syndrome Type 4
por: Virzì, Grazia Maria, et al.
Publicado: (2010)

Biological Efficacy and Safety of Niacinamide in Patients With ADPKD
por: El Ters, Mireille, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3esdj9uud5366lrhdokvqbe8q4